Synonyms: Example 1 (WO2011029803)
Compound class:
Synthetic organic
Comment: First published reports of this compound described it as a BACE1 inhibitor, but it was later identified as a BACE2 inhibitor as example 1 (with IC50 9 nM) from patent WO2011029803 [1]. It is also published as compound J from the BACE2 diabetes target paper [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Beauchamp J et al. (2011)
2 -aminodihydro [1, 3] thiazines as BACE2 inhibitors for the treatment of diabetes. Patent number: WO2011029803. Assignee: Roche. Priority date: 31/10/2014. Publication date: 17/03/2011. |
2. Esterházy D, Stützer I, Wang H, Rechsteiner MP, Beauchamp J, Döbeli H, Hilpert H, Matile H, Prummer M, Schmidt A et al.. (2011)
Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass. Cell Metab, 14 (3): 365-77. [PMID:21907142] |